vs

Side-by-side financial comparison of IHS Holding Ltd (IHS) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $254.0M, roughly 1.3× IHS Holding Ltd). On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 0.1%). IHS Holding Ltd produced more free cash flow last quarter ($178.6M vs $-133.8M).

IHS Towers is one of the largest independent owners, operators and developers of shared communications infrastructure in the world, with operations across Africa and Latin America. It is the fifth-largest independent multinational tower company in the world.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

IHS vs MDGL — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.3× larger
MDGL
$321.1M
$254.0M
IHS
Growing faster (revenue YoY)
MDGL
MDGL
+210.7% gap
MDGL
210.8%
0.1%
IHS
More free cash flow
IHS
IHS
$312.4M more FCF
IHS
$178.6M
$-133.8M
MDGL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IHS
IHS
MDGL
MDGL
Revenue
$254.0M
$321.1M
Net Profit
$-58.6M
Gross Margin
83.6%
Operating Margin
-18.6%
Net Margin
-18.2%
Revenue YoY
0.1%
210.8%
Net Profit YoY
1.4%
EPS (diluted)
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IHS
IHS
MDGL
MDGL
Q4 25
$254.0M
$321.1M
Q3 25
$455.1M
$287.3M
Q2 25
$433.3M
$212.8M
Q1 25
$439.6M
$137.3M
Q4 24
$253.8M
$103.3M
Q3 24
$420.3M
$62.2M
Q2 24
$435.4M
Q1 24
$417.7M
$0
Net Profit
IHS
IHS
MDGL
MDGL
Q4 25
$-58.6M
Q3 25
$147.4M
$-114.2M
Q2 25
$32.3M
$-42.3M
Q1 25
$30.7M
$-73.2M
Q4 24
$-59.4M
Q3 24
$-205.7M
$-107.0M
Q2 24
$-124.3M
Q1 24
$-1.6B
$-147.5M
Gross Margin
IHS
IHS
MDGL
MDGL
Q4 25
83.6%
Q3 25
47.5%
Q2 25
51.3%
Q1 25
51.4%
96.7%
Q4 24
72.1%
Q3 24
52.0%
Q2 24
52.5%
Q1 24
39.1%
Operating Margin
IHS
IHS
MDGL
MDGL
Q4 25
-18.6%
Q3 25
35.1%
-39.7%
Q2 25
33.8%
-22.2%
Q1 25
37.1%
-57.8%
Q4 24
-64.8%
Q3 24
29.9%
-187.1%
Q2 24
34.0%
Q1 24
-1.7%
Net Margin
IHS
IHS
MDGL
MDGL
Q4 25
-18.2%
Q3 25
32.4%
-39.8%
Q2 25
7.5%
-19.9%
Q1 25
7.0%
-53.4%
Q4 24
-57.5%
Q3 24
-48.9%
-172.0%
Q2 24
-28.5%
Q1 24
-372.8%
EPS (diluted)
IHS
IHS
MDGL
MDGL
Q4 25
$-2.55
Q3 25
$0.44
$-5.08
Q2 25
$0.10
$-1.90
Q1 25
$0.10
$-3.32
Q4 24
$-2.50
Q3 24
$-0.61
$-4.92
Q2 24
$-0.36
Q1 24
$-4.67
$-7.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IHS
IHS
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$825.7M
$198.7M
Total DebtLower is stronger
$3.1B
$339.9M
Stockholders' EquityBook value
$-89.8M
$602.7M
Total Assets
$4.5B
$1.3B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IHS
IHS
MDGL
MDGL
Q4 25
$825.7M
$198.7M
Q3 25
$647.6M
$295.7M
Q2 25
$531.8M
$186.2M
Q1 25
$629.0M
$183.6M
Q4 24
$578.0M
$100.0M
Q3 24
$397.5M
$232.7M
Q2 24
$445.7M
Q1 24
$333.2M
$622.5M
Total Debt
IHS
IHS
MDGL
MDGL
Q4 25
$3.1B
$339.9M
Q3 25
$3.3B
$339.8M
Q2 25
$3.2B
$118.4M
Q1 25
$3.4B
$118.0M
Q4 24
$3.3B
$117.6M
Q3 24
$3.5B
$117.1M
Q2 24
$3.6B
Q1 24
$3.5B
$116.1M
Stockholders' Equity
IHS
IHS
MDGL
MDGL
Q4 25
$-89.8M
$602.7M
Q3 25
$38.1M
$625.7M
Q2 25
$-98.4M
$696.0M
Q1 25
$-184.4M
$710.6M
Q4 24
$-314.4M
$754.4M
Q3 24
$-284.7M
$777.2M
Q2 24
$-308.3M
Q1 24
$-163.2M
$850.8M
Total Assets
IHS
IHS
MDGL
MDGL
Q4 25
$4.5B
$1.3B
Q3 25
$4.7B
$1.4B
Q2 25
$4.5B
$1.0B
Q1 25
$4.4B
$996.6M
Q4 24
$4.2B
$1.0B
Q3 24
$4.6B
$1.1B
Q2 24
$4.5B
Q1 24
$4.6B
$1.1B
Debt / Equity
IHS
IHS
MDGL
MDGL
Q4 25
0.56×
Q3 25
85.85×
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IHS
IHS
MDGL
MDGL
Operating Cash FlowLast quarter
$246.9M
$-133.5M
Free Cash FlowOCF − Capex
$178.6M
$-133.8M
FCF MarginFCF / Revenue
70.3%
-41.7%
Capex IntensityCapex / Revenue
26.9%
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$718.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IHS
IHS
MDGL
MDGL
Q4 25
$246.9M
$-133.5M
Q3 25
$251.3M
$79.8M
Q2 25
$237.7M
$-47.1M
Q1 25
$200.3M
$-88.9M
Q4 24
$344.4M
$-104.5M
Q3 24
$174.5M
$-67.0M
Q2 24
$134.7M
Q1 24
$75.8M
$-149.2M
Free Cash Flow
IHS
IHS
MDGL
MDGL
Q4 25
$178.6M
$-133.8M
Q3 25
$189.2M
$79.0M
Q2 25
$197.7M
Q1 25
$153.2M
Q4 24
$282.9M
$-104.7M
Q3 24
$122.3M
$-67.8M
Q2 24
$74.2M
Q1 24
$14.8M
$-149.5M
FCF Margin
IHS
IHS
MDGL
MDGL
Q4 25
70.3%
-41.7%
Q3 25
41.6%
27.5%
Q2 25
45.6%
Q1 25
34.8%
Q4 24
111.5%
-101.3%
Q3 24
29.1%
-109.0%
Q2 24
17.0%
Q1 24
3.5%
Capex Intensity
IHS
IHS
MDGL
MDGL
Q4 25
26.9%
0.1%
Q3 25
13.6%
0.3%
Q2 25
9.2%
0.0%
Q1 25
10.7%
0.0%
Q4 24
24.2%
0.2%
Q3 24
12.4%
1.3%
Q2 24
13.9%
Q1 24
14.6%
Cash Conversion
IHS
IHS
MDGL
MDGL
Q4 25
Q3 25
1.70×
Q2 25
7.36×
Q1 25
6.52×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IHS
IHS

Segment breakdown not available.

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons